CAPPED BONUS CERTIFICATE - ARGENX SE Stock

Certificat

FA40S

NLSGE001BMN3

Market Closed - Euronext Paris 07:13:23 2024-01-30 EST
4.16 ^EUR	-0.24%

1 month	+2.46%
3 months	-7.04%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ARGENX SE

Chart CAPPED BONUS CERTIFICATE - ARGENX SE

Latest news about ARGENX SE

European Equities Close Lower in Tuesday Trading; UK Regulators Probe Microsoft's Licensing Deal With Inflection	12:15pm	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	11:20am	MT
Transcript : Argenx SE - Special Call	08:30am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Big Bank Earnings Roll in Amid Rising Hopes of Rate Cuts	08:29am	MT

More news

Static data

Product type	Bonus- and Part-Guarantee-Certificates
Buy / Sell	CALL
Underlying	ARGENX SE
Issuer	Société Générale
	FA40S
ISIN	NLSGE001BMN3
Date issued	2023-08-21
Strike	510 €
Maturity	2024-12-20 (157 Days)
Parity	100 : 1
Emission price	4.51 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	4.695 €
Lowest since issue	3.02 €

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Sector

More about the company